Trademark Attorney / Law Firm

EUGENE MOROZ – Trademark Portfolio

EUGENE MOROZ has filed 3 trademarks with the United States Patent and Trademark Office (USPTO). Filing records span from 1988 to 1997, covering 2 years of intellectual property practice. The portfolio covers 3 Nice Classification classes, with the highest concentration in Class 1 (Chemicals, 1 filings) and Class 42 (Computer & Scientific, 1 filings).

3 Total Trademarks
Loading...
By Date
By Name
Filter by Class:

Practice Areas by Trademark Class

EUGENE MOROZ's trademark practice covers 3 Nice Classification classes, representing the range of industries and goods/services handled in their USPTO filings.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademark applications has EUGENE MOROZ filed?

EUGENE MOROZ has filed 3 trademark applications with the United States Patent and Trademark Office (USPTO).

What trademark classes does EUGENE MOROZ specialize in?

EUGENE MOROZ has filed trademarks across 3 Nice Classification classes. The most common practice areas include Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

How long has EUGENE MOROZ been filing trademarks?

EUGENE MOROZ's trademark filing history with the USPTO spans from 1988 to 1997, covering 9 years of trademark practice. During this period, EUGENE MOROZ has handled 3 trademark applications.

What is EUGENE MOROZ's trademark registration success rate?

EUGENE MOROZ has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.